- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 6, 2018
Translation in Brief
Opening chromatin: long-term detriment?
Enhancing chromatin accessibility in cancer could be a liability, not a benefit
BioCentury | Aug 11, 2016
Distillery Therapeutics
Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)
BioCentury | Jan 14, 2016
Distillery Therapeutics
Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)
BioCentury | Jan 8, 2015
Distillery Therapeutics
Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)
Items per page:
1 - 10 of 14